Headline Results From CHANT Safety And Tolerability Study In Intracerebral Hemorrhage (ICH) Show NXY-059 Achieved Key Endpoints

... AstraZeneca announced results from the phase IIb safety and tolerability trial for NXY-059in acute intracerebral hemorrhage (ICH) patients, CHANT (Cerebral HemorrhagicAnd NXY-059 Treatment). Although AstraZeneca is developing NXY-059 for thetreatment of Acute Ischemic Stroke (AIS), it was felt important to assess thesafety and tolerability of NXY-059 in ICH, as treatment may be initiated priorto a neuroimaging confirmation of the diagnosis of AIS... click link for more info. ...